Refine
Year of publication
Document Type
- Article (61)
- Preprint (57)
- diplomthesis (1)
Has Fulltext
- yes (119)
Is part of the Bibliography
- no (119)
Keywords
- Liver diseases (4)
- liver transplantation (4)
- Cirrhosis (3)
- Liver transplantation (3)
- COVID-19 (2)
- Dirac (2)
- Dirac-Brueckner theory (2)
- Dirac-Brückner Theorie (2)
- Hadron (2)
- Hadron-Hadron Scattering (2)
- Hepatitis C virus (2)
- Hepatocellular carcinoma (2)
- Kerne (2)
- Lagrangian (2)
- Quanten-Chromodynamik (2)
- Quantenchromodynamik (2)
- Quantum Chromodynamics (2)
- Quark Gluon Plasma (2)
- SARS-CoV-2 (2)
- Zustandsgleichungen (2)
- baryon (2)
- biliary stricture (2)
- cirrhosis (2)
- dense matter (2)
- dichte Materie (2)
- hadron (2)
- heavy ion collisions (2)
- influenza (2)
- nuclear matter (2)
- nuclei (2)
- out-patient paediatrics (2)
- quark gluon plasma (2)
- relativistic (2)
- respiratory tract infection (2)
- 15-PGDH (1)
- ACLF (1)
- Anti-Kaon (1)
- Antikaon (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Artificial Intelligence (1)
- Autologous stem cell transplantation (1)
- Binding analysis (1)
- Biodiversity Data (1)
- Biomarker (1)
- Biomonitoring (1)
- Blood (1)
- Botanical Collections (1)
- CLIF-C ACLF score (1)
- CLIF-C ACLF-R score (1)
- CNS melanoma (1)
- CT (1)
- Cancer treatment (1)
- Cell signalling (1)
- Chaperones (1)
- Chlorides (1)
- Computed axial tomography (1)
- Conservation (1)
- Crystal structure (1)
- DNA methylation (1)
- DYRK1A (1)
- Death rates (1)
- Diabetes mellitus (1)
- Dichte (1)
- Digitization (1)
- Distributed software development (1)
- Elementarteilchen (1)
- Elementary particle (1)
- Endocrine cancer (1)
- Energie (1)
- Etiology (1)
- European registry for idiopathic pulmonary fibrosis (eurIPFreg) (1)
- Geometrical modelling (1)
- Geometrisches Modellieren (1)
- HIV (1)
- HIV-1 (1)
- Hadron Materie (1)
- Hartree (1)
- Herbaria (1)
- High performance liquid chromatography (1)
- High-dose chemotherapy (1)
- Hispanic people (1)
- Hydrogen bonding (1)
- Hypermaterie (1)
- Idiopathic pulmonary fibrosis (IPF) (1)
- IgG4-related disease (1)
- Immune suppression (1)
- Immunology (1)
- Indeterminate biliary stricture (1)
- Indoles (1)
- Infectious disease epidemiology (1)
- Inhaltsanalyse (1)
- Inklusion (1)
- Integration, (1)
- Interstitial lung diseases (ILD) (1)
- J/ϕ (1)
- K-Meson (1)
- Kaon (1)
- Kaons (1)
- Kernmaterie (1)
- Kinase inhibitors (1)
- Kinases (1)
- Kollision (1)
- Kollisionen schwerer Ionen (1)
- Lagrangian . equation of state (1)
- Lehrer*innenbildung (1)
- Lenalidomide (1)
- Mechanisms of disease (1)
- Membrane staining (1)
- Methicillin-resistant Staphylococcus aureus (1)
- Multiple myeloma (1)
- Negative staining (1)
- Nephrons (1)
- Neuroendocrine cancer (1)
- Neutronenstern (1)
- Next-generation sequencing (1)
- Objectoriented technology (1)
- Objektorientierte Technologie (1)
- Oncology (1)
- PCR (1)
- PGE2 (1)
- Particle interactions (1)
- Partikel-Wechselwirkungen (1)
- Plasma (1)
- Portal hypertension (1)
- QCD (1)
- QGP signals (1)
- Quantum Chromodynamic (1)
- Quantum chromodynamics (1)
- Quark (1)
- Quark Materie (1)
- Quark gluon Plasma (1)
- Radiation exposure (1)
- Radical nephrectomy (1)
- Raum Zeit (1)
- Relapse (1)
- Renal cancer (1)
- Renal system (1)
- Research Infrastructure (1)
- SU (3) - Modell (1)
- SU (3) - Symmetrie (1)
- SU (3) Modell (1)
- SU(3) model (1)
- SU(3)-model (1)
- SU(3)-symmetry (1)
- Second-line treatment (1)
- Semantics (1)
- Simulation (1)
- Software engineering (1)
- Softwaretechnik (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival analysis (1)
- Taxonomy (1)
- Walecka-Modell (1)
- Walecka-model (1)
- acoustic radiation force impulse (1)
- acute-on-chronic liver failure (1)
- alkaloid (1)
- anti-kaon (1)
- antikaon (1)
- antimicrobial stewardship (1)
- bile duct stenosis (1)
- carbapenem resistance (1)
- chemical (1)
- chemotherapy (1)
- chiral SU (3) (1)
- chiral SU(3) (1)
- chiral SU(3) model (1)
- cholangiocarcinoma (1)
- chronic hepatitis C (1)
- co-crystallization (1)
- collision (1)
- coloured quark dynamic (1)
- computed tomography (1)
- conceptualization (1)
- critical care unit (1)
- critical ill patients (1)
- cyclin Y (1)
- death rates (1)
- dense (1)
- dileptons (1)
- direct antiviral agents (1)
- direct-acting antiviral (DAA) treatment (1)
- docking studies (1)
- double-pigtail stents (1)
- endoscopic retrograde cholangiography (1)
- endoscopic retrograde cholangiopancreatography (1)
- endoscopy (1)
- energy (1)
- enterobacter infections; pseudomonas aeruginosa; epidemiology (1)
- eosinophilic cholangitis (1)
- epidemiology (1)
- equation of state (1)
- fibrocytes (1)
- flow (1)
- graft rejection (1)
- hadron matter (1)
- hadronic (1)
- hadronic matter (1)
- hadronische Materie (1)
- harmine (1)
- head-and-neck cancer (1)
- heavy-ion collisions (1)
- heiße und dichte Materie (1)
- hepatitis C (1)
- hitze (1)
- hot (1)
- hot and dense matter (1)
- hypermatter (1)
- idiopathic pulmonary fibrosis (1)
- immunohistochemistry (1)
- inclusion (1)
- infection control (1)
- integrin (1)
- interferon-free antiviral treatment (1)
- intrahepatic cholangiocarcinoma (1)
- ischemic type biliary lesions (1)
- kaon (1)
- kaons (1)
- liver cirrhosis (1)
- liver fibrosis (1)
- lung cancer (1)
- mechanical ventilation (1)
- medical risk factors (1)
- meson (1)
- metastasis (1)
- microsatellite instability (1)
- monoamine oxidase A (1)
- multidrug resistance (1)
- neutron star (1)
- orthopic liver transplantation (1)
- outside-in signaling (1)
- overall survival (1)
- particle ratios (1)
- plasma (1)
- portal hypertension (1)
- primary sclerosing cholangitis (1)
- proteomics (1)
- pseudomonas aeruginosa (1)
- pulmonary failure (1)
- quark (1)
- quark matter (1)
- recurrent cholangitis (1)
- relativistische (1)
- respiratory failure (1)
- schwere Ion-Kollisionen (1)
- sepsis (1)
- short-course antibiotic therapy (1)
- space-time (1)
- sphingolipids (1)
- spreading (1)
- stent patency (1)
- strange (1)
- strangeness (1)
- structure–activity relationships (1)
- subjektives Begriffsverständnis (1)
- superheavy (1)
- superheavy nuclei (1)
- superschwer (1)
- superschwere Kerne (1)
- teacher training (1)
- thermal (1)
- transient elastography (1)
- transmission (1)
- whole-genome sequencing (1)
Institute
We compute the vacuum polarization correction to the binding energy of nuclear matter in the Walecka model using a nonperturbative approach. We first study such a contribution as arising from a ground-state structure with baryon-antibaryon condensates. This yields the same results as obtained through the relativistic Hartree approximation of summing tadpole diagrams for the baryon propagator. Such a vacuum is then generalized to include quantum effects from meson fields through scalar-meson condensates which amounts to summing over a class of multiloop diagrams. The method is applied to study properties of nuclear matter and leads to a softer equation of state giving a lower value of the incompressibility than would be reached without quantum effects. The density-dependent effective sigma mass is also calculated including such vacuum polarization effects.
A first testing ground for QED in the combined presence of a strong Coulomb field and a strong magnetic field is provided by the precise measurement of the hyperfine structure splitting of hydrogenlike 209Bi. We present a complete calculation of the one-loop self-energy correction to the first-order hyperfine interaction for various nuclear charges. In the low-Z regime we almost perfectly agree with the Z alpha expansion, but for medium and high Z there is a substantial deviation.
We investigate the production of heavy quarks in continuum and bound states in nuclear collisions. Creation rates for free bb and tt quark pairs and for bottomonium and toponium in the ground state are computed at energies of the BNL Relativistic Heavy Ion Collider, CERN Large Hadron Collider (LHC), and Superconducting Super Collider. Central and peripheral heavy-ion collisions are discussed. For top-quark creation we assumed a mass range of 90≤mt≤250 GeV. The creation rate for top quarks in peripheral collisions is estimated to be by a factor 40 to 130 smaller compared with corresponding central collisions. For mt=130 GeV we calculated a creation rate of about 4760 top-quark pairs per day at the LHC (3.5 TeV/nucleon) for Pb-Pb collisions.
We calculate the asymptotic high-energy amplitude for electrons scattering at one ion, as well as at two colliding ions, by means of perturbation theory. We show that the interaction with one ion eikonalizes and that the interaction with two ions causally decouples. We are able to put previous results on perturbative grounds and propose further applications for the obtained rules for interactions on the light cone. We discuss the implications of the eikonal amplitude on the pair production probability in ultrarelativistic peripheral heavy-ion collisions. In this context the Weizsäcker-Williams method is shown to be exact in the ultrarelativistic limit, irrespective of the produced particles’ mass. A new equivalent single-photon distribution is derived, which correctly accounts for Coulomb distortions. The impact on single-photon induced processes is discussed.
A calculation of the vacuum-polarization contribution to the hyperfine splitting for hydrogenlike atoms is presented. The extended nuclear charge distribution is taken into account. For the experimentally interesting case 209Bi82+ we predict a delta-lambda- -1.6 nm shift for the transition wavelength of the ground-state hyperfine splitting.
Intrahepatic cholangiocarcinoma (iCCA) is the most frequent subtype of cholangiocarcinoma (CCA), and the incidence has globally increased in recent years. In contrast to surgically treated iCCA, data on the impact of fibrosis on survival in patients undergoing palliative chemotherapy are missing. We retrospectively analyzed the cases of 70 patients diagnosed with iCCA between 2007 and 2020 in our tertiary hospital. Histopathological assessment of fibrosis was performed by an expert hepatobiliary pathologist. Additionally, the fibrosis-4 score (FIB-4) was calculated as a non-invasive surrogate marker for liver fibrosis. For overall survival (OS) and progression-free survival (PFS), Kaplan–Meier curves and Cox-regression analyses were performed. Subgroup analyses revealed a median OS of 21 months (95% CI = 16.7–25.2 months) and 16 months (95% CI = 7.6–24.4 months) for low and high fibrosis, respectively (p = 0.152). In non-cirrhotic patients, the median OS was 21.8 months (95% CI = 17.1–26.4 months), compared with 9.5 months (95% CI = 4.6–14.3 months) in cirrhotic patients (p = 0.007). In conclusion, patients with iCCA and cirrhosis receiving palliative chemotherapy have decreased OS rates, while fibrosis has no significant impact on OS or PFS. These patients should not be prevented from state-of-the-art first-line chemotherapy.
Mapping cortical brain asymmetry in 17,141 healthy individuals worldwide via the ENIGMA Consortium
(2017)
Background and Aims: In patients with advanced liver cirrhosis due to chronic hepatitis C virus (HCV) infection antiviral therapy with peginterferon and ribavirin is feasible in selected cases only due to potentially life-threatening side effects. However, predictive factors associated with hepatic decompensation during antiviral therapy are poorly defined.
Methods: In a retrospective cohort study, 68 patients with HCV-associated liver cirrhosis (mean MELD score 9.18±2.72) were treated with peginterferon and ribavirin. Clinical events indicating hepatic decompensation (onset of ascites, hepatic encephalopathy, upper gastrointestinal bleeding, hospitalization) as well as laboratory data were recorded at baseline and during a follow up period of 72 weeks after initiation of antiviral therapy. To monitor long term sequelae of end stage liver disease an extended follow up for HCC development, transplantation and death was applied (240weeks, ±SD 136weeks).
Results: Eighteen patients (26.5%) achieved a sustained virologic response. During the observational period a hepatic decompensation was observed in 36.8%. Patients with hepatic decompensation had higher MELD scores (10.84 vs. 8.23, p<0.001) and higher mean bilirubin levels (26.74 vs. 14.63 µmol/l, p<0.001), as well as lower serum albumin levels (38.2 vs. 41.1 g/l, p = 0.015), mean platelets (102.64 vs. 138.95/nl, p = 0.014) and mean leukocytes (4.02 vs. 5.68/nl, p = 0.002) at baseline as compared to those without decompensation. In the multivariate analysis the MELD score remained independently associated with hepatic decompensation (OR 1.56, 1.18–2.07; p = 0.002). When the patients were grouped according to their baseline MELD scores, hepatic decompensation occurred in 22%, 59%, and 83% of patients with MELD scores of 6–9, 10–13, and >14, respectively. Baseline MELD score was significantly associated with the risk for transplantation/death (p<0.001).
Conclusions: Our data suggest that the baseline MELD score predicts the risk of hepatic decompensation during antiviral therapy and thus contributes to decision making when antiviral therapy is discussed in HCV patients with advanced liver cirrhosis.
Objectives: The aim of this multicenter retrospective study was to investigate safety and efficacy of direct acting antiviral (DAA) treatment in the rare subgroup of patients with HCV/HIV-coinfection and advanced liver cirrhosis on the liver transplant waiting list or after liver transplantation, respectively.
Methods: When contacting 54 German liver centers (including all 23 German liver transplant centers), 12 HCV/HIV-coinfected patients on antiretroviral combination therapy were reported having received additional DAA therapy while being on the waiting list for liver transplantation (patient characteristics: Child-Pugh A (n = 6), B (n = 5), C (n = 1); MELD range 7–21; HCC (n = 2); HCV genotype 1a (n = 8), 1b (n = 2), 4 (n = 2)). Furthermore, 2 HCV/HIV-coinfected patients were denoted having received DAA therapy after liver transplantation (characteristics: HCV genotype 1a (n = 1), 4 (n = 1)).
Results: Applied DAA regimens were SOF/DAC (n = 7), SOF/LDV/RBV (n = 3), SOF/RBV (n = 3), PTV/r/OBV/DSV (n = 1), or PTV/r/OBV/DSV/RBV (n = 1), respectively. All patients achieved SVR 12, in the end. In one patient, HCV relapse occurred after 24 weeks of SOF/DAC therapy; subsequent treatment with 12 weeks PTV/r/OBV/DSV achieved SVR 12. One patient underwent liver transplantation while on DAA treatment. Analysis of liver function revealed either stable parameters or even significant improvement during DAA therapy and in follow-up. MELD scores were found to improve in 9/13 therapies in patients on the waiting list for liver transplantation; in only 2 patients a moderate increase of MELD scores persisted at the end of follow-up.
Conclusion: DAA treatment was safe and highly effective in this nation-wide cohort of patients with HCV/HIV-coinfection awaiting liver transplantation or being transplanted.